A- A A+

Rigid opiate agonist treatment programmes risk denying people their agency 

Chang J. 

BMJ 2023; 380 :p400 doi:10.1136/bmj.p400 


Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study

Edward Suarez, Jr., Tyler S. Bartholomew, Marina Plesons, Katrina Ciraldo, Lily Ostrer, David P. Serota, Teresa A. Chueng, Morgan Frederick, Jason Onugha & Hansel E. Tookes (2023)

Annals of Medicine, 55:1, 733-743, DOI: 10.1080/07853890.2023.2182908


Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020. 

Diaz L, Eiden C, Jouanjus E, Frauger E, Fouilhé N, Djezzar S, Gibaja V, Boucher A, Le Boisselier R, Libert F, Caous AS, Monzon E, Guerlais M, Daveluy A, Fauconneau B, Peyrière H. 

Therapie. 2023 Feb 15:S0040-5957(23)00030-6. doi: 10.1016/j.therap.2023.02.002. Epub ahead of print. PMID: 36918317.



Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-2017. 

Larney, S, Jones, NR, Hickman, M, Nielsen, S, Ali, R, Degenhardt, L. 

Addiction. 2023; 000– 0. doi.org/10.1111/add.16178


Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions. 

Thomas CP, Stewart MT, Ledingham E, Adams RS, Panas L, Reif S. 

JAMA Netw Open. 2023;6(3):e232052. doi:10.1001/jamanetworkopen.2023.2052


Characteristics of Fatal Poisonings Among Infants and Young Children in the United States.

Christopher E. Gaw, Allison E. Curry, Kevin C. Osterhoudt, Joanne N. Wood, Daniel J. Corwin; 

Pediatrics2023; e2022059016. 10.1542/peds.2022-059016


Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy

Krawczyk, Noa et al.

The Lancet Public Health, Volume 8, Issue 3, e238 - e246 


Webinar. Treatment Considerations in the Age of Fentanyl 

Fentanyl and other high-potency synthetic opioids are increasingly present in the U.S. drug supply. Healthcare systems, treatment providers, and justice systems are grappling with the physiological consequences of chronic fentanyl use and how its use may impact treatment.

Presenters will discuss practical clinical practice-based guidance on treating opioid use disorder in the age of fentanyl, the use of medications for opioid use disorder (MOUD) in the treatment of individuals using fentanyl, and other considerations and challenges. The free webinar from the Justice Community Opioid Innovation Network (JCOIN) at the National Institute on Drug Abuse (NIDA), in partnership with the American Academy of Addiction Psychiatry (AAAP), the Providers Clinical Support System (PCSS) and the Addiction Policy Forum.


Spülen nicht Putzen: Sublinguales Buprenorphin schlägt auf die Zähne

Bereits 2022 hatte die FDA auf Grundlage von Fallmeldungen Alarm geschlagen, nun hat eine kanadisch/US-amerikanische Studie die Vermutungen bestätigt: Sublinguales Buprenorphin kann die Zähne schädigen. Welche Empfehlungen können Anwender:innen mitgegeben werden? (DAZ – Deutsche Apothekerzeitung, 07.03.2023)


FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain 

Benefits for use outweigh these risks and oral care can help. (FDA – Food and Drugs Administration, USA, 21.01.2023)


Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease. 

Etminan M, Rezaeianzadeh R, Kezouh A, Aminzadeh K. 

JAMA. 2022;328(22):2269–2271. doi:10.1001/jama.2022.17485



Xylazine: What Does the Emergence of this New Contaminant Mean for People Who Use Drugs and Health Care Providers?

Throughout the past year, a substance called xylazine has been saturating the drug supply in many parts of the United States. Xylazine is a powerful sedative used in veterinary medicine, typically for larger animals like horses and cattle. It is not considered to be safe for humans. However, the drug has been found to be present in many instances of heroin, fentanyl, and cocaine overdose. (Ireta, USA, 17.02.2023)


Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study. 

Bapir L, Erridge S, Nicholas M, Pillai M, Dalavaye N, Holvey C, Coomber R, Hoare J, Khan S, Weatherall MW, Rucker JJ, Platt M, Sodergren MH. 

Expert Rev Neurother. 2023 Feb 26:1-15. doi: 10.1080/14737175.2023.2181696. Epub ahead of print. PMID: 36803620.


An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. 

Olsson F, Erridge S, Tait J, Holvey C, Coomber R, Beri S, Hoare J, Khan S, Weatherall MW, Platt M, Rucker JJ, Sodergren MH. 

Expert Rev Clin Pharmacol. 2023 Mar 3:1-10. doi: 10.1080/17512433.2023.2183841. Epub ahead of print. PMID: 36848456.



CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study. 

Müller-Vahl KR, Pisarenko A, Szejko N, Haas M, Fremer C, Jakubovski E, Musil R, Münchau A, Neuner I, Huys D, van Elst LT, Schröder C, Ringlstetter R, Koch A, Jenz EB, Großhennig A. 

Psychiatry Res. 2023 Feb 28;323:115135. doi: 10.1016/j.psychres.2023.115135. Epub ahead of print. PMID: 36878177.


Entzündliche Darmerkrankungen: Kann Cannabis das Sterberisiko senken?

Philadelphia – US-Patienten mit Morbus Crohn oder Colitis ulcerosa, die zur Behandlung anderer Erkrankungen Cannabis konsumierten, hatten in einer retrospektiven Studie, deren Ergebnisse in einem Poster auf der Tagung der „European Crohn's and Colitis Organisation“ in Kopenhagen vorgestellt wurden, ein niedrigeres Sterberisiko, und sie verursachten geringere Krankenkosten (Journal of Crohn's and Colitis 2023, DOI: 10.1093/ecco-jcc/jjac190.0962). Ein Beweis für eine günstige Wirkung von Cannabis ist dies jedoch nicht. (aerzteblatt.de, 06.03.2023)


The impact of recreational cannabis markets on motor vehicle accident, suicide, and opioid overdose fatalities. 

Marinello S, Powell LM. 

Soc Sci Med. 2023 Mar;320:115680. doi: 10.1016/j.socscimed.2023.115680. Epub 2023 Jan 16. PMID: 36764087.


Cannabis legalization and cannabis use, daily cannabis use and cannabis-related problems among adults in Ontario, Canada (2001-2019). 

Imtiaz S, Nigatu YT, Ali F, Douglas L, Hamilton HA, Rehm J, Rueda S, Schwartz RM, Wells S, Elton-Marshall T. 

Drug Alcohol Depend. 2023 Mar 1;244:109765. doi: 10.1016/j.drugalcdep.2023.109765. Epub 2023 Jan 6. PMID: 36652851.


The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment. 

Lawn, W, Trinci, K, Mokrysz, C, Borissova, A, Ofori, S, Petrilli, K, et al. 

Addiction. 2023. doi.org/10.1111/add.16154


FDA. Information about Naloxone

Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for overdose. In the wake of the opioid epidemic, efforts are underway to make this emergency treatment more readily available and more accessible. (FDA – Food and Drug Adminstration, USA, aufgerufen 12.03.2023)


 ‘The area I’m from is very rough’: Drug users’ views on the role of social and economic factors in their experiences of drug-related harm, 

Shane O’Mahony (2023) 

Journal of Ethnicity in Substance Abuse, DOI: 10.1080/15332640.2023.2177919


From punishment to help? Continuity and change in the Norwegian decriminalization reform proposal. 

Kammersgaard T. 

Int J Drug Policy. 2023 Feb 8;113:103963. doi: 10.1016/j.drugpo.2023.103963. Epub ahead of print. PMID: 36764027.


Opioid overdose risk 10 times greater for those recently released from prison, research shows

People recently released from prison in Oregon face a risk for opioid overdose 10 times greater than the general public, according to a new study led by an Oregon State University College of Pharmacy scientist.  (MedicalXpress, USA, 08.03.2023)


EMCDDA. Women and drugs: health and social responses

This miniguide is one of a larger set, which together comprise Health and social responses to drug problems: a European guide. It provides an overview of the most important aspects to consider when planning or delivering health and social responses for women who use drugs, and reviews the availability and effectiveness of the responses. It also considers implications for policy and practice. (EMCDDA, last update: 08.03.2023)


Medscape's medical reference app.

Search for 9,200+ drugs by tapping the Drugs icon in your app. Plus, follow news in any clinical specialty. Get essential point-of-care drugs information now.

9,200+ Rx and OTC drugs, herbals, and supplements

7,500+ Reference articles for decision-making support

Clinical tools: drug interaction checker, 450+ medical calculators, and pill identifier

(Medscape, USA, aufgerufen am 12.03.2023)


Webinar. EMCDDA webinar on Responding to stimulant use: developments in treatment 22nd March 2023 h.12.00-13.30

In this webinar, we will begin our conversation with updates on the research, discussing the results of the latest systematic reviews and highlighting ongoing European studies. We will then bridge the gap between research and practice, learning from the experience of treating methamphetamine-related problems with prescription stimulants as well as identifying key policy and practice questions. (EMCDDA, Lissabon)


Veranstaltungskalender von infodrog (Schweiz)


Werden drogenkonsumierende Menschen stigmatisiert – insbesondere vom Fachpersonal? 

Menschen mit Abhängigkeitserkrankungen sind zahlreichen Vorurteilen ausgesetzt. In einer Studie wurden Fachpersonen von Akutspitälern und Behörden sowie Patient:innen eines Ambulatoriums der Universitären Psychiatrischen Kliniken Basel befragt, wie Menschen mit einer Abhängigkeitserkrankung Stigmatisierung im Kontakt mit sozialen Institutionen, Krankenhäusern und Behörden wahrnehmen. Über 70 % der befragten Patient:innen fühlen sich aufgrund ihrer Abhängigkeitserkrankung stigmatisiert. Je mehr Betroffene Stigmatisierungen durch ihr psychosoziales Hilfesystem erfahren, desto weniger nehmen sie Unterstützungsangebote an. (STEPHANIE BUSCHNER-FEHR, THOMAS MÜLLER, OTTO SCHMID in: Suchtmagazin, Schweiz, 2023-1, Jg. 49, S. 11 – 15)


Substances from unregulated drug markets - A retrospective data analysis of customer-provided samples from a decade of drug checking service in Zurich (Switzerland). 

Magnolini R, Schneider M, Schori D, Trachsel D, Bruggmann P.

Int J Drug Policy. 2023 Feb 23;114:103972. doi: 10.1016/j.drugpo.2023.103972. Epub ahead of print. PMID: 36841217.